The generic drug, developed by Roxane Laboratories, is intended to treat excessive daytime sleepiness and cataplexy, which causes a sudden loss of muscle control, in patients with narcolepsy.
Jazz Pharma’s shares fell 6.6 percent to $108 in after-hours trading on Tuesday in response to the approval.
More articles on suppy chain:
Pfizer CEO responds to Trump’s threats against pharma: ‘We need to raise prices’
Short seller predicts Lannett will be first drugmaker to go bankrupt amid price scrutiny
Washington, D.C.-area hospitals desperate for blood donations ahead of inauguration
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
